{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/TYRA",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Tyra Biosciences, Inc. (NASDAQ: TYRA) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Tyra Biosciences, Inc., listed on NASDAQ under the ticker TYRA, with ISIN US90240B1061. The LEI is not on the record, as no GLEIF record with the exact legal name in jurisdiction US-DE exists. The security type is Corporate, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Delaware. The segment is not on the record. The listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 87 filings across 49 filing days in the twelve months to 2026-11-08. Filings by type are 37 regulatory filings, 32 directors' dealings, 6 results, 3 corporate news, 3 director changes, 3 prospectuses and 3 AGM/EGM filings. The median gap between filing days is 4.0 days. The latest filing is a regulatory filing dated 2026-10-27, which is 12 days before the record date. The exchange median is 6.0 days cadence, 52 filings and 5.0 days latency across 4,359 issuers on NASDAQ. The sector median is 6.0 days cadence, 63.0 filings and 4.0 days latency across 526 issuers in 2834 Pharmaceutical Preparations.\n\n## Auditor\n\nThe auditor of record is Ernst & Young LLP, located in San Diego, California. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nNo research houses were found on the issuer's investor-relations page.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe issuer is held in sealed years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001863127.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/TYRA (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1863127/000119312526085490/tyra-20251231.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/TYRA (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1863127/000119312526085490/tyra-20251231.htm",
    "state": "sourced",
    "value": "Ernst & Young LLP"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1863127/000119312526085490/tyra-20251231.htm",
    "state": "sourced",
    "value": "San Diego, California"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/TYRA",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 3,
    "corporate_news": 3,
    "director_change": 3,
    "directors_dealings": 32,
    "prospectus": 3,
    "regulatory_filing": 37,
    "results": 6
   },
   "cadence_median_gap_days": 4,
   "filing_days": 49,
   "filings": 87,
   "latency_days": 12,
   "latest": [
    {
     "category": "SCHEDULE 13G/A",
     "date": "2026-10-27",
     "source": "https://www.sec.gov/Archives/edgar/data/1863127/000201238326003856/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G/A",
     "type": "regulatory_filing"
    },
    {
     "category": "SCHEDULE 13G",
     "date": "2026-09-21",
     "source": "https://www.sec.gov/Archives/edgar/data/1863127/000092189526002613/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G",
     "type": "regulatory_filing"
    },
    {
     "category": "SCHEDULE 13D/A",
     "date": "2026-09-17",
     "source": "https://www.sec.gov/Archives/edgar/data/1863127/000134682426000237/xslSCHEDULE_13D_X02/primary_doc.xml",
     "title": "SCHEDULE 13D/A",
     "type": "regulatory_filing"
    },
    {
     "category": "4",
     "date": "2026-09-17",
     "source": "https://www.sec.gov/Archives/edgar/data/1863127/000123191926001194/xslF345X06/form4-09172026_080941.xml",
     "title": "4",
     "type": "directors_dealings"
    },
    {
     "category": "4",
     "date": "2026-09-17",
     "source": "https://www.sec.gov/Archives/edgar/data/1863127/000119312526394738/xslF345X06/ownership.xml",
     "title": "4 — 4",
     "type": "directors_dealings"
    }
   ],
   "latest_filing_date": "2026-10-27",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/TYRA",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-09-25",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US90240B1061"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001863127.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001863127.json",
    "state": "sourced",
    "value": "Tyra Biosciences, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001863127.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001863127.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "TYRA"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:b1a30d6c44d36db38a2fed2f4f3deea1224f6c081b4d2184b2aa6d491f4b42e9",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/TYRA",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:b1a30d6c44d36db38a2fed2f4f3deea1224f6c081b4d2184b2aa6d491f4b42e9",
 "path": "/us/NASDAQ/TYRA",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Tyra Biosciences, Inc., listed on NASDAQ under the ticker TYRA, with ISIN US90240B1061. The LEI is not on the record, as no GLEIF record with the exact legal name in jurisdiction US-DE exists. The security type is Corporate, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Delaware. The segment is not on the record. The listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 87 filings across 49 filing days in the twelve months to 2026-11-08. Filings by type are 37 regulatory filings, 32 directors' dealings, 6 results, 3 corporate news, 3 director changes, 3 prospectuses and 3 AGM/EGM filings. The median gap between filing days is 4.0 days. The latest filing is a regulatory filing dated 2026-10-27, which is 12 days before the record date. The exchange median is 6.0 days cadence, 52 filings and 5.0 days latency across 4,359 issuers on NASDAQ. The sector median is 6.0 days cadence, 63.0 filings and 4.0 days latency across 526 issuers in 2834 Pharmaceutical Preparations.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Ernst & Young LLP, located in San Diego, California. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the issuer's investor-relations page.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The issuer is held in sealed years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001863127.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/TYRA"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1863127/000119312526085490/tyra-20251231.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/TYRA"
  }
 ],
 "title": "Tyra Biosciences, Inc. (TYRA) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}